Valuation: BioNTech SE

Capitalization 2.28TCr 2.62TCr 2.14TCr 1.95TCr 3.6TCr 2,27200Cr 4.06TCr 25TCr 9.71TCr 1,04100Cr 9.84TCr 9.63TCr 3,82600Cr P/E ratio 2025 *
-22.9x
P/E ratio 2026 * -20.7x
Enterprise value 1.25TCr 1.44TCr 1.18TCr 1.07TCr 1.98TCr 1,24700Cr 2.23TCr 14TCr 5.33TCr 57TCr 5.4TCr 5.29TCr 2,10000Cr EV / Sales 2025 *
5.59x
EV / Sales 2026 * 5.9x
Free-Float
86.48%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.04%
1 week-0.04%
Current month+11.19%
1 month+7.53%
3 months+11.69%
6 months-5.79%
Current year-6.51%
More quotes
1 week 102.24
Extreme 102.24
107.51
1 month 93.5
Extreme 93.5
122.9
Current year 81.2
Extreme 81.2
129.27
1 year 76.53
Extreme 76.5301
131.49
3 years 76.53
Extreme 76.5301
188.98
5 years 51.81
Extreme 51.8101
464
10 years 12.52
Extreme 12.525
464
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 01/01/2018
Chief Executive Officer 59 02/06/2008
Director of Finance/CFO 61 01/07/2021
Director TitleAgeSince
Chairman 54 02/06/2008
Director/Board Member 68 02/06/2008
Director/Board Member 64 01/01/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+2.04%-0.04%+25.86%-13.85% 2.62TCr
-0.75%-3.69%-51.60%-13.14% 5.39TCr
-0.44%-6.27%+26.71%+39.09% 3.32TCr
+0.52%-4.39%+61.20%-30.38% 2.61TCr
+3.24%+4.00%+51.02%+427.38% 1.95TCr
+1.98%+3.94%+159.27%+1,803.70% 1.53TCr
-1.78%-7.02%-23.75%-35.98% 1.31TCr
0.00%-13.93%+107.76%-65.12% 1.25TCr
-0.91%-2.93%+81.85%+99.95% 1.1TCr
-0.81%-4.75%+156.10%+312.19% 1.04TCr
Average +0.31%-3.54%+59.44%+252.38% 2.21TCr
Weighted average by Cap. +0.29%-3.34%+33.34%+173.59%
See all sector performances

Financials

2025 *2026 *
Net sales 223.5Cr 257.67Cr 210.53Cr 191.29Cr 353.89Cr 22TCr 398.74Cr 2.49TCr 954.06Cr 10TCr 966.84Cr 946.25Cr 38TCr 225.06Cr 259.47Cr 212Cr 192.63Cr 356.37Cr 22TCr 401.53Cr 2.51TCr 960.74Cr 10TCr 973.61Cr 952.88Cr 38TCr
Net income -97Cr -111.39Cr -91Cr -83Cr -152.99Cr -9.65TCr -172.37Cr -1.08TCr -412.44Cr -4.42TCr -417.96Cr -409.06Cr -16TCr -97Cr -111.9Cr -91Cr -83Cr -153.69Cr -9.69TCr -173.17Cr -1.08TCr -414.33Cr -4.44TCr -419.88Cr -410.94Cr -16TCr
Net Debt -1.03TCr -1.18TCr -966.86Cr -878.5Cr -1.63TCr -1,02500Cr -1.83TCr -11TCr -4.38TCr -47TCr -4.44TCr -4.35TCr -1,72600Cr -947.34Cr -1.09TCr -892.36Cr -810.81Cr -1.5TCr -95TCr -1.69TCr -11TCr -4.04TCr -43TCr -4.1TCr -4.01TCr -1,59300Cr
More financial data * Estimated data
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
6,772
More about the company
Date Price Change Volume
20/25/20 106.53 $ +2.04% 7,22,511
18/25/18 104.40 $ -0.54% 8,95,041
17/25/17 104.97 $ -1.28% 7,65,503
16/25/16 106.33 $ -0.23% 12,40,114

Delayed Quote Nasdaq, June 21, 2025 at 01:30 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
92.40EUR
Average target price
116.95EUR
Spread / Average Target
+26.56%
Consensus

Quarterly revenue - Rate of surprise